News
UBX
1.470
-1.34%
-0.020
UNITY BIOTECHNOLOGY : BELIEVE THAT CURRENT CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES ARE SUFFICIENT TO FUND OPERATIONS INTO Q3 OF 2025
Reuters · 1d ago
Weekly Report: what happened at UBX last week (0415-0419)?
Weekly Report · 3d ago
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Price target for Amgen Inc. Slashed from $370 to $360. Morgan Stanley raised the price target for Antero Resources Corporation. Urban Outfitters, Inc. Shares fell 0.5% to close at $38.02 on Tuesday. The price target was cut for Unity Biotechnology, Inc.'s shares.
Benzinga · 04/17 12:21
HC Wainwright & Co. Maintains Buy on Unity Biotechnology, Lowers Price Target to $8
Benzinga · 04/17 09:53
Unity Biotechnology Price Target Cut to $8.00/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 04/16 11:15
Unity Biotechnology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/16 11:15
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
TipRanks · 04/16 10:31
UNITY BIOTECHNOLOGY INC <UBX.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $8 FROM $10
Reuters · 04/16 10:09
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
Unity Biotechnology reported earnings per share of -28 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Unity Biotechnology's results were above the analyst estimate for EPS of -72 cents. The company just reported results for fourth quarter.
Investorplace · 04/15 15:52
Unity Biotechnology, Inc. Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023
Press release · 04/15 14:24
UNITY Biotechnology Inc reports results for the quarter ended in December - Earnings Summary
UNITY Biotechnology Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 28 cents per share. The mean expectation of four analysts was for the company to report a loss of 72 cents. The average analyst rating on the shares is "strong buy"
Reuters · 04/15 12:00
Unity Biotechnology Q4 2023 GAAP EPS $(0.28) May Not Be Comparable To $(0.77) Estimate
Benzinga · 04/15 11:22
Unity Biotechnology GAAP EPS of -$0.28 beats by $0.49
Seeking Alpha · 04/15 11:10
UNITY BIOTECHNOLOGY INC - QTRLY SHR LOSS $0.28
Reuters · 04/15 11:00
*Unity Biotechnology 4Q Loss/Shr 28c >UBX
Dow Jones · 04/15 11:00
Press Release: UNITY Biotechnology, Inc. Reports -2-
Unity Biotechnology, Inc. Reported a net loss for the quarter ended December 31, 2018. The company has a total of 15,743,772 assets. The company's total assets include cash and cash equivalents, long-term and short-term investments, securities, and other assets. The Company has no debt and no debt. Unity Biotechnology has no current assets.
Dow Jones · 04/15 11:00
Weekly Report: what happened at UBX last week (0408-0412)?
Weekly Report · 04/15 09:16
Weekly Report: what happened at UBX last week (0401-0405)?
Weekly Report · 04/08 09:17
More
Webull provides a variety of real-time UBX stock news. You can receive the latest news about Unity Btech through multiple platforms. This information may help you make smarter investment decisions.
About UBX
Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.